| OBSERVATION'S |
the split is almost dead even between generics and exclusive synthesis, a balance that contact says the company wants to maintain for optimum resource allocation.
"We control the generic--how much we make, how much is in inventory. "When we work for clients in custom synthesis, they tell us when they want the product. They are waiting on results from clinical studies and don't want to invest until they have concrete results." European firms say they generally avoid the kind of deals Pisgah, Regis, and PolyCarbon have entered--those in which generics are made exclusively for one customer. Although there are exceptions, Co.`s contact tries not to be tied to one company, "so as to give ourselves the best opportunity to make a success out of the business."
|